OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Neuropathic Pain (Neuralgia). According to GlobalData, Phase I drugs for Neuropathic Pain (Neuralgia) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OCT-461201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OCT-461201 overview
OCT-461201 is under development for the treatment of neuropathic and visceral pain, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), chemotherapy induced peripheral neuropathy (CIPN) and post-herpetic neuralgia. It acts by targeting cannabinoid receptor 2 (CB2). It was also under development for the treatment of post-herpetic neuralgia.
Oxford Cannabinoid Technologies overview
Oxford Cannabinoid Technologies is a biopharmaceutical company focused on researching, developing and licensing cannabinoid-based compounds and therapies. Oxford Cannabinoid Technologies is headquartered in Oxford, Greater London, the UK.
For a complete picture of OCT-461201’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
